Home » Newsletters » BioWorld Science

BioWorld Science

March 2, 2017

View Archived Issues

Opiant receives FDA feedback on development of OPNT-002 for alcohol use disorder

Novel fixed dose combination EHCV shows promise against chronic hepatitis C in clinical study

Amgen reports overall survival data from ENDEAVOUR study of Kyprolis

GS-PI-1 is a promising new generation HIV PI with favorable potency and resistance barrier

Promising results from the BCN02-Romi study of MVA.HIVconsv vaccine

Invenra and QIMR Berghofer collaborate to discover therapeutic antibodies

Bristol-Myers Squibb announces investment and plans for collaboration with Grail

EMA grants PRIME access to givosiran for acute hepatic porphyrias

European Commission approves Vihuma

European Commission grants orphan drug designation to apatinib for gastric cancer

Audentes initiates LUSTRO study in Crigler-Najjar syndrome

Pivotal Phase III study results for Merck & Co.'s varicella zoster virus vaccine presented

Arrakis Therapeutics completes Series A financing

SB-913 from Sangamo Therapeutics granted U.S. orphan drug designation for the treatment of MPS II

Boehringer Ingelheim's BI-836858 given U.S. orphan drug designation for the treatment of MDS

Sellas reports updated phase II data on galinpepimut-S in multiple myeloma

European Commission grants orphan drug designation to ZX-008 for Lennox-Gastaut syndrome

FDA grants priority review to enasidenib NDA

Pfizer and iTeos Therapeutics identify tryptophan 2,3-dioxygenase inhibitors

Eli Lilly completes acquisition of CoLucid Pharmaceuticals

Hetero Research Foundation discloses novel antiviral agents

FDA allows PR-022 to proceed to phase II study for the treatment of atopic dermatitis

Myovant initiates phase III trial of relugolix for advanced prostate cancer

Toray Industries initiates first-in-human study of TRK-950 in advanced solid tumors

Intensity Therapeutics studies intratumorally dosed INT-230-6 in advanced cancers

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 11, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Italy’s Angelini pays $4.1B cash for rare disease specialist Catalyst
BioWorld
Italian family-owned Angelini Pharma SpA is making its first move into the U.S. market, acquiring rare diseases specialist Catalyst Pharma Inc. in an all-cash...